WuXi Biologics and Fresenius Sign an Agreement
WuXi Biologics and Fresenius have signed an agreement.
Related stories
Nongshim Sues U.S. Government for Trump Tariff Refunds
L impact | EQUITY | Nov 03, 2026, 04:44 AM UTC
KG DongbuSteel Q3 Operating Profit Falls 52.5% Year Over Year
M impact | EQUITY | Nov 03, 2026, 04:42 AM UTC
Huaxin Building Materials Plans to Acquire Stake in Brazilian Cement Company
Huaxin Building Materials plans to acquire an equity stake in a Brazilian cement company.
M impact | EQUITY | Nov 03, 2026, 04:42 AM UTC
Akums Drugs, VRL Logistics and KRBL Rally Up to 11% After Q2 Earnings
Akums Drugs, VRL Logistics and KRBL shares rallied up to 11% after strong second-quarter earnings, according to the headline.
M impact | EQUITY | Nov 03, 2026, 04:42 AM UTC
Jupiter Wagons Gains 2%; KEC International Slides 7% After Weak Q2 Earnings
Jupiter Wagons shares rose 2% after receiving an LOI from GATX India for 10 ACT2 wagons. KEC International shares fell 7% after weak second-quarter earnings.
M impact | EQUITY | Nov 03, 2026, 04:41 AM UTC
BLS Polymers Shares Begin Trading at 65% Premium to Issue Price
BLS Polymers began trading at ₹248 per share on the NSE, at a 65% premium to its issue price.
M impact | EQUITY | Nov 03, 2026, 04:41 AM UTC